Procaps Group SA

Procaps Group SA is an international healthcare and pharmaceutical company. The firm is engaged in the developing of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It operates through the following segments: NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics. The NextGel segment is involved in the manufacturing and distribution of prescription and over-the-counter pharmaceutical products in USA, Brazil, and Colombia. The Procaps Colombia segment is focused on the manufacturing and distribution of prescription and over-the-counter pharmaceutical products in Colombia. The CAN segment deals with the manufacturing and distribution of prescription and over-the-counter pharmaceutical products in Northern Central America: Salvador, Guatemala, Nicaragua, and Honduras. The CASAND segment offers pharmaceutical products in Southern Central America that include Panama and Costa Rica, and the North Andes District that include Ecuador, Peru, and Bolivia. The Diabetrics segment consists of the diabetes solutions and chronic disease management tool. The company was founded by Ruben Minski in 1977 and is headquartered in Luxembourg.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MIAMI and BARRANQUILLA, Colombia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, providing critical updates on the Company's ongoing independent investigation, financial restatement, governance enhancements, and commitment to long-term stability.

Procaps Issues Shareholder Letter Update

MIAMI and BARRANQUILLA, Colombia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, addressing the current state of the business and outlining key strategic priorities for the Company.

Procaps Issues Shareholder Letter

Harmony Biosciences Holdings

Incyte

MiMedx Group

MEI Pharma

SCYNEXIS

United Therapeutics

Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.

7 Undervalued Biotech Stocks to Buy for Big-Time Returns

MIAMI & BARRANQUILLA, Columbia--(BUSINESS WIRE)--Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that Mr. Ruben Minski has resigned from his role as Executive Chairman of the Board, effective June 30th. Mr. Minski will continue to serve as a member of the Board of Directors. Reflecting on his decision, Ruben stated: “This month marked six months since Jose Antonio Vieira assumed the role of CEO of.

Procaps Group Announces New Chairman

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Receives Nasdaq Notice Related to Late Filing of its Form 20-F.

Procaps Group Receives Nasdaq Notice Related to Late Filing of its Form 20-F

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Delays Filing of Annual Report on Form 20-F.

Procaps Group Delays Filing of Annual Report on Form 20-F

MIAMI & BARRANQUILLA, Colombia.--(BUSINESS WIRE)--Dear Shareholders, We became aware on Saturday, January 13, 2024, that the online voting instructions related to the upcoming General Meeting of Shareholders of the Company scheduled for January 22, 2024, were incorrect. Notwithstanding the Company's diligent review of all relevant materials, a third party unilaterally included on the online version an inaccurate statement that the Board of Directors of the Company had recommended a vote in favo.

Procaps Group – Notice to Shareholders

Procaps Group, S.A. (PROC) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.05 per share.

Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Reports Third Quarter 2023 Results.

Procaps Group Reports Third Quarter 2023 Results

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Statement from the Board of Directors of Procaps Group.

Statement from the Board of Directors of Procaps Group

Agreement Combines Procaps Oral Delivery System Technology and Manufacturing with Genomma's Strategic Marketing and Distribution Footprint BARRANQUILLA, Colombia and MEXICO CITY and MIAMI , Nov. 29, 2023 /PRNewswire/ -- Procaps Group (NASDAQ: PROC) ("Procaps"), a leading integrated international healthcare and pharmaceutical services company, and Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB; "Genomma"), the leading pharmaceutical and personal care company in Latin America, today announced a strategic agreement to develop, manufacture and market five Softgel products within Latin America.

Procaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin America

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024.

Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Update on Third Quarter Results.

Procaps Group Update on Third Quarter Results

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group to Report Third Quarter and Nine Months Results on Tuesday November 14 and Host Conference Call on Thursday November 16 at 10:30a.m. ET.

Procaps Group to Report Third Quarter and Nine Months 2023 Results on Tuesday November 14, 2023

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Wins First Place in Ranking of Innovative Companies in the Pharma Sector in Colombia.

Procaps Group Wins First Place in Ranking of Innovative Companies in the Pharma Sector in Colombia

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today that it will participate at the CPHI Barcelona 2023, that will take place from October 24th to October 26th, continuing with our two-decade presence in the conference. We welcome you to learn more on our specialized technologies and capabilities such as our novel oral delivery system formulations, gummies, development o.

Procaps Group to Participate at CPHI Barcelona 2023

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group to Host Webinar on Colombian Pharma Market Tuesday, October 10, 2023 at 10:00 a.m. Eastern Time.

Procaps Group to Host Webinar on Colombian Pharma Market

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group to Participate at BTG 2023 LatAm CEO Conference and Roth 2023 Healthcare Opportunities Conference in October.

Procaps Group to Participate at BTG 2023 LatAm CEO Conference and Roth 2023 Healthcare Opportunities Conference in October

MIAMI & BARRANQUILLA, Columbia--(BUSINESS WIRE)--Procaps Group Announces the Expansion of its Oncology Portfolio.

Procaps Group Announces the Expansion of its Oncology Portfolio

Procaps Group S.A. (NASDAQ:PROC ) Q2 2023 Earnings Call Transcript September 5, 2023 11:00 AM ET Company Participants Melissa Angelini - IR Director Ruben Minski - CEO Patricio Vargas - CFO Conference Call Participants Kemp Doliver - Brookline Capital Markets Operator Good day, and welcome to the Procaps Group Business Update Call and Webcast.

Procaps Group S.A. (PROC) Q2 2023 Earnings Call Transcript

Procaps Group, S.A. (PROC) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.06 per share.

Procaps Group, S.A. (PROC) Q2 Earnings Surpass Estimates

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Reports Second Quarter 2023 Results.

Procaps Group Reports Second Quarter 2023 Results

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group to Report Second Quarter and First Half 2023 Results and Host Conference Call on Tuesday.

Procaps Group to Report Second Quarter and First Half 2023 Results and Host Conference Call on Tuesday

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group Publishes White Paper on Innovative Gummy Technology.

Procaps Group Publishes White Paper on Innovative Gummy Technology

B2Gold

Butler National Corporation

Globalstar

GEE Group

Jerash holdings (US) Inc

PaySign Inc

Bottom-fishers, take note: there are scores of penny stock opportunities out there. While major stocks have been on a year so far this year, penny stocks (or stocks trading for $5 per share or less) have delivered a more mixed performance.

News for Procaps Group SA Stock (PROC)